Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients

Phase 4

Completed

Conditions: Acute Pain
Postoperative Pain
Head and Neck Cancer

Interventions: Drug: Placebo
Drug: Gabapentin

Registration Number: NCT02926573

Lead Sponsor: Washington University School of Medicine

Brief Summary: Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care. Furthermore, at the core of a healthcare team and healthcare system is the desire to provide patients with the best possible care in order to achieve the best possible outcomes. Providers have the duty to identify areas of needed improvement within the domains of treatment. An area of need that is ubiquitous within medicine is pain control; in this case acute postoperative pain control is the targeted condition. Studies have already shown that better control of acute postoperative pain leads to shortened hospital stays, reduced hospital costs and patient morbidity, improved patient satisfaction and a reduced likelihood of developing chronic pain. Research within the field of pain management has definitively revealed that a combination of different medication regimens can control acute postoperative pain better than narcotics alone. In particular, the medication gabapentin has been shown to improve acute postop pain in many kinds of surgical settings, and it is a safe medication with arguably fewer side effects than narcotics. The investigators know that certain groups of post surgical otolaryngology patients can be at risk for high levels of postoperative pain. Given all of this information, physicians have a responsibility to utilize medications such as gabapentin to do a better job of controlling patient's pain. This investigation is a quality improvement project designed to elucidate the benefits of gabapentin in pain management in patients undergoing surgery of the head and neck mucosal surfaces. It will provide much needed data in an understudied population and ultimately will improve the practice of pain management, patient satisfaction and quality of care delivered in the Barnes otolaryngology department.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 123

Inclusion Criteria

Subjects undergoing definitive mucosal head and neck resection including oral cavity, oropharynx, larynx, and hypopharynx
At least one night of planned inpatient stay

Exclusion Criteria

Incapable of giving informed consent
Age less than 18
Glomerular Filtration Rate (GFR) less than 30
Allergy to gabapentin
Baseline gabapentin or lyrica use
Chronic opioid use for over six months

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo liquid by mouth or Per Tube twice a day
Gabapentin	Gabapentin	Gabapentin liquid by mouth or Per Tube 300mg twice a day

Primary Outcome Measures

Name	Time	Method
Change in Daily Narcotic Consumption	Daily from date of randomization until post-op day 2 or date of discharge, whichever comes first.	Total amount of narcotic use in morphine equivalents will be divided by the total hours of inpatient hospitalization, multiplied by 24 hours, to obtain the daily narcotic consumption.

Secondary Outcome Measures

Name	Time	Method
Patient Reported Post-treatment Pain Satisfaction as Measured by Overall Pain Control	Once on post-op day 2 or day of discharge, whichever comes first	-A discharge survey to document patient satisfaction and perceived pain control was given at the time of the last VAS score.
Mean Pain With Resting Score as Measured by VAS	Baseline through post operative day 3	* Subjective pain scores were captured using the Visual Analog Scale (VAS). Subjects were asked to "Please rate your current pain level with no movement (rest), with a cough, and with a swallow". Subjects marked a point on a 100-mm line anchored "no pain" on the left end and "worst possible pain" on the right end. * Pain literature reports that scores in the 10-30mm range correlate clinically with mild pain, in the 30-60 or 70mm range with moderate pain, and in the \>70 range with severe pain
Mean Pain With Coughing Score as Measured by VAS	Baseline through post operative day 3	* Subjective pain scores were captured using the Visual Analog Scale (VAS). Subjects were asked to "Please rate your current pain level with no movement (rest), with a cough, and with a swallow". Subjects marked a point on a 100-mm line anchored "no pain" on the left end and "worst possible pain" on the right end. * Pain literature reports that scores in the 10-30mm range correlate clinically with mild pain, in the 30-60 or 70mm range with moderate pain, and in the \>70 range with severe pain
Patient Reported Post-treatment Pain Satisfaction as Measured by How Often the Participant's Pain Was Well Controlled	Once on post-op day 2 or day of discharge, whichever comes first	-A discharge survey to document patient satisfaction and perceived pain control was given at the time of the last VAS score.
Patient Reported Post-treatment Pain Satisfaction as Measured by How Often the Hospital Staff Did Everything They Could do to Help the Participant's Pain	Once on post-op day 2 or day of discharge, whichever comes first	-A discharge survey to document patient satisfaction and perceived pain control was given at the time of the last VAS score.
Mean Pain With Swallowing Score as Measured by VAS	Baseline through post operative day 3	* Subjective pain scores were captured using the Visual Analog Scale (VAS). Subjects were asked to "Please rate your current pain level with no movement (rest), with a cough, and with a swallow". Subjects marked a point on a 100-mm line anchored "no pain" on the left end and "worst possible pain" on the right end. * Pain literature reports that scores in the 10-30mm range correlate clinically with mild pain, in the 30-60 or 70mm range with moderate pain, and in the \>70 range with severe pain